Head of NAFDAC advocates 200 billion naira lifeline for Nigerian pharma firms
The Director-General of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC), Paul Orhii, has said there was need for 200 billion naira ($1.27 billion) intervention for pharmaceutical companies as it would turn Nigeria from a drug importer to exporter of quality products, reports the local Vanguard newspaper.
Speaking on behalf of the DG earlier this week, NAFDAC deputy director, public relations, Abubakar Jimoh, stressed that with the injection of funds, pharmaceutical companies in the country will equip their factories to meet up with World Health Organization’s requirements.
He expressed delight that three Nigerian pharmaceutical companies were on the verge of receiving WHO certification, adding that NAFDAC’s goal was to increase the number of drug manufacturers that could meet the standard of the United Nations’ agency, the Vanguard noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze